{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:14:29Z","timestamp":1762870469485,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T00:00:00Z","timestamp":1647648000000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JMV-Journal de M\u00e9decine Vasculaire"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jdmv.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T15:09:14Z","timestamp":1615129754000},"page":"66-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia"],"prefix":"10.1016","volume":"46","author":[{"given":"G.","family":"Sarlon-Bartoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sarlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carcopino-Tusoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Suchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Morange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdmv.2021.02.002_bib0125","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0130","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","article-title":"Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0135","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"year":"2014","series-title":"asigna: Annex I. Summary of Product Characteristics","author":"EMA","key":"10.1016\/j.jdmv.2021.02.002_bib0140"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0145","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0150","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0155","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0160","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ejh.12096","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study","volume":"90","author":"Levato","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0175","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11523-016-0417-x","article-title":"Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy","volume":"11","author":"Bondon-Guitton","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0180","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0185","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/fcp.12102","article-title":"Are nilotinib-associated vascular adverse events an under-estimated problem?","volume":"29","author":"St\u00e8ve-Dumont","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0195","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bulcan.2015.11.008","article-title":"Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the [France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques]","volume":"103","author":"Rea","year":"2016","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0200","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0205","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0210","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1161\/01.CIR.103.17.2171","article-title":"Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis. The Troms\u00f8 Study","volume":"103","author":"Mathiesen","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0215","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/STROKEAHA.114.006091","article-title":"Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic review and meta-analysis","volume":"46","author":"Gupta","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0220","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0225","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3324\/haematol.2014.104075","article-title":"Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia","volume":"99","author":"Rea","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0230","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/CIRCRESAHA.109.207357","article-title":"Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis","volume":"105","author":"Franco","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0235","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"5","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jdmv.2021.02.002_bib0240","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"}],"container-title":["JMV-Journal de M\u00e9decine Vasculaire"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542451321000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542451321000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:05:31Z","timestamp":1762869931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542451321000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2542451321000262"],"URL":"https:\/\/doi.org\/10.1016\/j.jdmv.2021.02.002","relation":{},"ISSN":["2542-4513"],"issn-type":[{"type":"print","value":"2542-4513"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"JMV-Journal de M\u00e9decine Vasculaire","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdmv.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}